How HTLV-I Tax and HBZ control telomerase activity to induce adult T-cell leukemia

NIH RePORTER · NIH · R01 · $346,995 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY/ABSTRACT The human T-cell leukemia virus type I (HTLV-I) is an onco-retrovirus that infects and transforms human CD4 T cells in vitro and in vivo. HTLV-I is the etiological agent of adult T-cell leukemia/lymphoma (ATLL), an aggressive and invariably fatal hematological disease. The virus is transmitted through sexual contact, contaminated blood and mother-to-child by breastfeeding, and is present in 20-30 million people worldwide. HTLV-I-mediated T-cell transformation arises from a multi-step oncogenic process in which the virus induces chronic T-cell proliferation, resulting in accumulation of genetic defects and deregulated cell growth. It is not yet fully understood how HTLV-I engenders ATLL, but the virus blocks the apoptotic network and expends the proliferative capacity of infected cells. HTLV-I infects and immortalizes primary human T cells in vitro and, after several months, these cells acquire the ability to grow in the absence of interleukin-2, referred to as transformation. We previously demonstrated that the viral oncogenic Tax can reactivate telomerase expression, an event required for long-term proliferation of HTLV-I-transformed cells in vitro and in vivo. This application will investigate the molecular events associated with deregulated telomerase activity and its role in the HTLV-I transformation process. Since telomerase reactivation represents one of the central steps in human carcinogenesis, results from this study will have broad application beyond viral oncogenesis.

Key facts

NIH application ID
9960440
Project number
5R01CA201309-05
Recipient
UNIVERSITY OF KANSAS MEDICAL CENTER
Principal Investigator
CHRISTOPHE P NICOT
Activity code
R01
Funding institute
NIH
Fiscal year
2020
Award amount
$346,995
Award type
5
Project period
2016-07-01 → 2022-06-30